RecruitingNCT05459597
Antiepileptic Drugs in Elderly Patients
Population Pharmacokinetics, Effectiveness and Safety of Antiepileptic Drugs in Elderly Patients
Sponsor
Wei Zhao
Enrollment
500 participants
Start Date
Jan 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose is to study the population pharmacokinetics, effectiveness and safety of antiepileptic drug (phenytoin, carbamazepine, lamotrigine, levetiracetam, parempanel, etc) in elderly patients and recommend optimized dosage regimens.
Eligibility
Min Age: 65 YearsMax Age: 100 Years
Inclusion Criteria3
- Age ≥65 years old;
- Diagnosed with epilepsy;
- Using antiepileptic drugs for treatment;
Exclusion Criteria4
- Patients who are expected to die within 48 hours;
- Patients with allergy to antiepileptic drugs;
- Patients receiving other investigational drugs;
- Other factors that the researcher considers unsuitable for inclusion.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGantiepileptic drugs
phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05459597